Abstract Details

Title The Symbol Digit Modalities Test (SDMT) Has Been the Standard Cognitive Measure Used in Multiple Sclerosis (MS) Clinical Trials: How Does It Correlate with Computerized Cognitive Screening Tools?

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 169

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Mark Gudesblatt, MD (South Shore Neurology Assoc. PC) PRESENTER	The institution of Dr. Gudesblatt has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for genentech. The institution of Dr. Gudesblatt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
Myassar Zarif	Myassar Zarif has nothing to disclose.
Barbara Bumstead, NP	Ms. Bumstead has nothing to disclose.
Marijean Buhse (Stony Brook University)	Marijean Buhse has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.
	No disclosure on file
Cynthia L. Sullivan, PhD (Neuropsychology Associates of Fairfax)	No disclosure on file
	No disclosure on file
Jeffrey A. Wilken, PhD (NAF)	No disclosure on file
Glen M. Doniger, PhD (NeuroTrax Israel Ltd.)	No disclosure on file
	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details